Robert Hariri Insider Buy
Robert Hariri is the director of Myos Corp. He lately made a purchase of 2,300 shares in the -listed company with the purchase value totalling about $6,170 USD. That is according to the SEC provided price of $2.7 per every share. He also obtained 44,150 shares that are worth approx $84,589 USD in the last month. This acquisition was reported on 30/09/2015 and is already filed with the U.S. SEC. The original document is at your disposal to the public here. Robert now has 92,364 shares accounting for 10%+ of the Company’s market cap
Myos Corp Sentiment and Fundamentals
Myos Corp’s stock price has dropped a colossal 40.31% in the last 25 days, and is currently in a strong and smooth bearish downtrend. The chart below depic our sophisticated stocks time-momentum model due to which we give the stock a “NEUTRAL” rating.
MYOS Corp NASDAQ:MYOS Firm Profile
MYOS Corporation is an early development-stage bionutritional and biotherapeutics company The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company has two marketed products: MYO-T12 and Cenegenics Muscle Formula. MYO-T12 is a myostatin inhibitor, which is distributed by Maximum Human Performance (MHP), principally in the United States under the brand name MYO-X to specialty retail and other outlets. Cenegenics Muscle Formula is distributed by Cenegenics Product and Lab Services, LLC (Cenegenics). The Company also has a product line, Re Muscle Health, which provides non-genetically modified organisms (non-GMO) protein bars, shakes, pudding mixes and ready-to-eat powders.
Company Website: MYOS Corp
Myos Corp has 9 employees. Currently its market value is: $8.89 million and it has 3.23 million outstanding shares. Today the company has 2.68% shareholders and the institutional ownership stands at 2.68%. Myos Corp was formed in Nevada on 2007-04-11. The stock closed at $2.68 yesterday and it had average 2 days volume of 3227 shares. It is down from the 30 days average shares volume of 3721. Myos Corp has a 52weeks low of $1.50 and a 52 weeks high of $14.61. The stock price is below the 200 days simple moving average.
Robert Hariri is also director of Bionik Laboratories Corp., Wafergen Bio-Systems, Inc., Ir Biosciences Holdings Inc.
* Represents the weighted average purchase price. Shares were acquired in multiple transactions at prices ranging from $2.60 per share to $2.66 per share. The reporting person undertakes to provide to the issuer - any security holder of the issuer - or the staff of the Securities and Exchange Commission - upon request - full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote
* Represents the weighted average purchase price. Shares were acquired in multiple transactions at prices ranging from $2.60 per share to $2.75 per share. The reporting person undertakes to provide to the issuer - any security holder of the issuer - or the staff of the Securities and Exchange Commission - upon request - full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
